Ivan V Zelepukin
Overview
Explore the profile of Ivan V Zelepukin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zelepukin I, Griaznova O, Shevchenko K, Ivanov A, Baidyuk E, Serejnikova N, et al.
Nat Commun
. 2022 Nov;
13(1):6910.
PMID: 36376302
Tumour microenvironment hinders nanoparticle transport deep into the tissue precluding thorough treatment of solid tumours and metastatic nodes. We introduce an anticancer drug delivery concept termed FlaRE (Flash Release in...
12.
Pastukhov A, Belyaev I, Bulmahn J, Zelepukin I, Popov A, Zavestovskaya I, et al.
Sci Rep
. 2022 Jun;
12(1):9129.
PMID: 35650237
Boron-based nano-formulations look very promising for biomedical applications, including photo- and boron neutron capture therapies, but the fabrication of non-toxic water-dispersible boron nanoparticles (NPs), which contain the highest boron atom...
13.
Griaznova O, Belyaev I, Sogomonyan A, Zelepukin I, Tikhonowski G, Popov A, et al.
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631580
Hybrid multimodal nanoparticles, applicable simultaneously to the noninvasive imaging and therapeutic treatment, are highly demanded for clinical use. Here, Fe-Au core-satellite nanoparticles prepared by the method of pulsed laser ablation...
14.
Mirkasymov A, Zelepukin I, Ivanov I, Belyaev I, Dzhalilova D, Trushina D, et al.
Int J Pharm
. 2022 May;
621:121795.
PMID: 35526695
The rapid elimination of systemically administered drug nanocarriers by the mononuclear phagocyte system (MPS) compromises nanomedicine delivery efficacy. To mitigate this problem, an approach to block the MPS has been...
15.
Lunin A, Sokolov I, Zelepukin I, Zubarev I, Yakovtseva M, Mochalova E, et al.
RSC Adv
. 2022 May;
10(12):7301-7312.
PMID: 35493903
Nanoparticles (NPs) that can provide additional functionality to the nanoagents derived from them, , cytotoxicity or imaging abilities, are in high demand in modern nanotechnology. Here, we report new spindle-like...
16.
Popov A, Swiatkowska-Warkocka Z, Marszalek M, Tselikov G, Zelepukin I, Al-Kattan A, et al.
Nanomaterials (Basel)
. 2022 Feb;
12(4).
PMID: 35214980
The combination of magnetic and plasmonic properties at the nanoscale promises the development of novel synergetic image-guided therapy strategies for the treatment of cancer and other diseases, but the fabrication...
17.
Proshkina G, Shramova E, Shilova M, Zelepukin I, Shipunova V, Ryabova A, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680384
Near-infrared phototherapy has great therapeutic potential for cancer treatment. However, for efficient application, in vivo photothermal agents should demonstrate excellent stability in blood and targeted delivery to pathological tissue. Here,...
18.
Zelepukin I, Yaremenko A, Ivanov I, Yuryev M, Cherkasov V, Deyev S, et al.
ACS Nano
. 2021 Jul;
15(7):11341-11357.
PMID: 34250790
Safe application of nanoparticles in medicine requires full understanding of their pharmacokinetics including catabolism in the organism. However, information about nanoparticle degradation is still scanty due to difficulty of long-term...
19.
Zelepukin I, Popov A, Shipunova V, Tikhonowski G, Mirkasymov A, Popova-Kuznetsova E, et al.
Mater Sci Eng C Mater Biol Appl
. 2021 Feb;
120:111717.
PMID: 33545869
Having plasmonic absorption within the biological transparency window, titanium nitride (TiN) nanoparticles (NPs) can potentially outperform gold counterparts in phototheranostic applications, but characteristics of available TiN NPs are still far...
20.
Mirkasymov A, Zelepukin I, Nikitin P, Nikitin M, Deyev S
J Control Release
. 2020 Dec;
330:111-118.
PMID: 33326812
Smart nanomaterials, contrast nanoparticles and drug nanocarriers of advanced targeting architecture were designed for various biomedical applications. Most of such agents demonstrate poor pharmacokinetics in vivo due to rapid elimination...